chf

Nexstim Plc Key Technology Patent granted in EU

on 05/10/2016 10:29
Strengthened patent estate around Nexstim’s cutting-edge technology and software
Read more

Mainstay Medical announces Half Year Financial Results

on 22/09/2016 10:33

ReActiv8-A Clinical Trial – Sustained Performance at One Year

on 20/09/2016 10:37
One-year data confirm clinically important, statistically significant, and lasting improvement in pain, disability and quality of life for people with Chronic Low Back Pain and limited treatment options
Read more

Nexstim Plc agrees the next steps of the NBT stroke de novo submission with the FDA

on 15/09/2016 15:56

Euroscreen completes enrolment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

on 14/09/2016 10:48
Study evaluating ESN364, a novel, non-hormonal small-molecule drug designed to block Hot Flashes avoiding Hormone Replacement Therapy (HRT), known to increase the incidence of cancer in menopausal women.
Read more